TY - JOUR
T1 - New drug candidates and therapeutic targets for tuberculosis therapy
AU - Zhang, Ying
AU - Post-Martens, Katrin
AU - Denkin, Steven
N1 - Funding Information:
This work was supported by NIH grants AI44063 and AI/HL49485 and Natural Science Foundation of China (30328031).
PY - 2006/1
Y1 - 2006/1
N2 - Despite advances in chemotherapy and the BCG (Bacillus Calmette- Guérin) vaccine, tuberculosis remains a significant infectious disease. Although it can be cured, the therapy takes at least 6-9 months, and the laborious and lengthy treatment brings with it dangers of noncompliance, significant toxicity and drug resistance. The increasing emergence of drug resistance and the problem of mycobacterial persistence highlight the need to develop novel TB drugs that are active against drug resistant bacteria but, more importantly, kill persistent bacteria and shorten the length of treatment. Recent new and exciting developments in tuberculosis drug discovery show good promise of a possible revolution in the chemotherapy of tuberculosis.
AB - Despite advances in chemotherapy and the BCG (Bacillus Calmette- Guérin) vaccine, tuberculosis remains a significant infectious disease. Although it can be cured, the therapy takes at least 6-9 months, and the laborious and lengthy treatment brings with it dangers of noncompliance, significant toxicity and drug resistance. The increasing emergence of drug resistance and the problem of mycobacterial persistence highlight the need to develop novel TB drugs that are active against drug resistant bacteria but, more importantly, kill persistent bacteria and shorten the length of treatment. Recent new and exciting developments in tuberculosis drug discovery show good promise of a possible revolution in the chemotherapy of tuberculosis.
UR - http://www.scopus.com/inward/record.url?scp=32444448306&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=32444448306&partnerID=8YFLogxK
U2 - 10.1016/S1359-6446(05)03626-3
DO - 10.1016/S1359-6446(05)03626-3
M3 - Review article
C2 - 16478687
AN - SCOPUS:32444448306
SN - 1359-6446
VL - 11
SP - 21
EP - 27
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 1-2
ER -